Alpha-synucleinopathies;Las α-sinucleinopatías

Neurologia

Volumn 16, Issue 4, 2001, Pages 163-170

  Ferrer, I ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

synuclein; A4 amyloid; Alzheimer disease; Glial cytoplasmic inclusion; Lewy body; Lewy body dementia; Multiple system atrophy; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID PROTEIN;

ALZHEIMER DISEASE; CELL INCLUSION; CELL SURVIVAL; CONFORMATION; CYTOPLASM; DIFFUSE LEWY BODY DISEASE; GLIA CELL; HUMAN; MOLECULAR WEIGHT; NERVE CELL; NEURITE; NEUROPATHY; OLIGODENDROGLIA; PARKINSON DISEASE; PROTEIN BINDING; REVIEW;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; CELL DEATH; CYTOPLASM; HUMANS; LEWY BODY DISEASE; MULTIPLE SYSTEM ATROPHY; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; NEUROGLIA; NEURONS; PARKINSON DISEASE; SYNUCLEINS;

EID: 0034978915     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (116)

1. Genetic classification of primary neurodegenerative disease
2. Synphilin-1 associates with asynuclein and promotes the formation of cytosolic inclusions
3. Synphilin-1 is present in Lewy bodies in Parkinson's disease
4. The synucleins: A family of proteins involved in synaptic function, plasticity, neurodegeneration and disease
5. Molecular cloning of a novel component of amyloid in Alzheimer's disease
6. Identification of two distinct synucleins from human brain
7. The NACP/synuclein gene: Chromosomal assignment and screening for alterations in Alzheimer disease
8. The human NACP/α-synuclein gene: Chromosomal assignement to 4q21.3-q22 and Taq1 RFLP analysis
9. Tissue-dependent alternative splicing of mRNA for NACP, the precursor of non-Aβ component of Alzheimer's disease amyloid
10. Alpha-synuclein in Lewy body disease and Alzheimer's disease
11. Non-Aβ component of Alzheimer's disease amyloid (NAC) is amyloidogenic
12. Mapping of a gene for Parkinson's disease to chromosome 4p21-q23
13. Mutation in the α-synuclein gene identified in families with Parkinson's disease
14. Ala30Pro mutation in the gene encoding αsynuclein in Parkinson's disease
15. Constitutive phosphorylation of the Parkinson's disease associated α-synuclein
16. Binding of encoding α-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation
17. Membrane association and protein conformation of αsynuclein in intact neurons. Effect of Parkinson's disease-linked mutations
18. Regulation of phospholipase D2: Selective inhibition of mammalian phospholipase D isoenzymes by α- and βsynucleins
19. Chaperone-like activity of synucleins
20. Mice lacking α-synuclein display functional deficits in the nigrostriatal system
21. Dopaminergic loss and inclusion body formation in α-synuclein mice: Implications for neurodegenerative disorders
22. A Drosophila model of Parkinson's disease
23. Expression pattern of the non-Aβ component of Alzheimer's disease amyloid precursor protein (NACP/α-synuclein) during brain development
24. α-Synuclein is expressed in a variety of brain tumors showing neuronal differentiation
25. Alpha-synuclein expression in central nervous system tumors showing neuronal or mixed neuronal/glial differentiation
26. α-Synuclein immunore-activity is present in axonal swellings in neuroaxonal dystrophy and acute traumatic brain injury
27. Experimental induction of alpha-synuclein in CNS neurons
28. α-Synuclein- positive structures induced by intraventricular infusion of leupeptin in rats
29. NACP, the precursor protein of non-amyloid β/A4 protein (Aβ) component of Alzheimer disease amyloid, binds Aβ and stimulates Aβ aggregation
30. Binding of Aβ to α- and β-synucleins: Identification of segments in α-synuclein/NAC precursor that bind Aβ in NAC
31. Self oligomerization of NACP, the precursor protein of the nonamyloid β/A4 protein (Aβ) component of Alzheimer's disease amyloid, observed in the presence of a C-terminal Aβ fragment (residues 25-35)
32. Plaque-associated α-synuclein (NACP) pathology in aged transgenic mice expressing amyloid precursor protein
33. Lewy bodies contain altered αsynuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes
34. α-Synuclein inclusions in Alzheimer and Lewy body diseases
35. α-Synuclein inclusions in amygdala in the brains of patients with the Parkinsonism-Dementia Complex of Guam
36. Synthetic filaments assembled from the C-terminally truncated α-synuclein
37. Human recombinant NACP is aggregated and fibrillated in vitro: Relevance for Lewy body disease
38. The role of α-synuclein in Parkinson's disease: A biophysical analogy to Aβ and Alzheimer's disease
39. Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease
40. Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease
41. Mutant and wild type human α-synuclein assemble into elongated filaments with distinct morphologies in vitro
42. Both familial Parkinson's disease mutations accelerate α-synuclein aggregation
43. Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid
44. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy
45. α-Synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP
46. MPTP induces α-synuclein aggregation in the substantia nigra of baboons
47. Parkinson's disease: A disorder due to nigral glutathione deficiency
48. Transition metals, ferritin, glutathione, and ascorbic acid in Parkinsonism brains
49. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia
50. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease
51. Parkinson's disease
52. Mitochondrial complex I deficiency in Parkinson's disease
53. Oxidation reactions in Parkinson's disease
54. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra
55. Glycosidation and oxidative stress in Parkinson disease and diffuse Lewy body disease
56. A generalized increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease
57. Oxidative DNA damage in the parkinsonian brain: An apparent selective increase in 8-hydroxyguanine levels in substantia nigra
58. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons
59. Role of cytochrome c as a stimulator of aggregation in Lewy body disease
60. α-Synuclein promotes mitochondrial deficit and oxidative stress
61. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminium in Parkinson's disease: A LAMMA study
62. The role of transition metals in the pathogenesis of Parkinson's disease
63. Sequestration of iron by Lewy bodies in Parkinson's disease
64. Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro
65. Aluminium-induced structural alterations of the precursor of the non-Aβ component of Alzheimer's disease amyloid
66. Copper(II)-induced self-oligomerization of α-synuclein
67. Signal changes on MRI and increases in reactive microgliosis, astrogliosis, and iron in the putamen of two patients with multiple system atrophy
68. α-Synuclein overexpression promotes aggregation of mutant huntingtin
69. Alpha-synuclein immunoreactivity of huntingtin polyglutamine aggregates in striatum and cortex of Huntington's disease patients and transgenic mouse models
70. Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer's disease
71. α-Eynuclein in Lewy bodies
72. NACP, a presynaptic protein, immuno-reactivity in Lewy bodies in Parkinson's disease
73. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies
74. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies
75. Nigral and cortical Lewy bodies in dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease Contain α-synuclein immuno-reactivity
76. Human NACP/α-synuclein distribution in Lewy body disease
77. Abnormal acccumulation of NACP/αsynuclein in neurodegenerative disorders
78. Immuno-electron microscopic demonstration of NACP/α-synuclein epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies
79. Aggregation of neurofilament and α-synuclein in Lewy bodies: Implicatuions for the pathogenesis of Parkinson disease and Lewy body dementia
80. Accumulation of α-synuclein/NACP is a cytopathological feature common to Lewy Body disease and multiple system atrophy
81. Purification of Lewy bodies and identification of α-synuclein as a major component of Lewy bodies
82. Involvement of α-synuclein in Parkinson's disease and other neurodegenerative disorders
83. Accumulation of NACP/α-synuclein in Lewy body disease and multiple system atrophy
84. Lewy-related dystrophic neurites in cerebral cortex of Parkinson's disease and diffuse Lewy body disease
85. α-Synuclein imunoreactivity in dementia with Lewy bodies: Morphological staging and comparison with ubiquitin immunostaining
86. NACP/α-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains
87. Alpha-synuclein fibrillary formation in the spinal cord of Parkinson's disease and multiple system atrophy
88. Alpha-synuclein accumulation in glial cells in the brain in Parkinson's disease
89. Widespread alterations of α-synuclein in multiple system atrophy
90. C-terminal α-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders
91. Distribution of argyrophilic glial inclusions in the brain of Lewy body disease
92. Antibodies to α-synuclein detect Lewy bodies in many Down syndrome brains with Alzheimer's disease
93. Lewy body in neunrodegeneration with brain iron accumulation type I is immunoreactive for α-synuclein
94. Widespread occurrence of α-synuclein/NACP-immunoreactive neuronal inclusions in juvenile and adult-onset Hallervorden-Spatz disease with Lewy bodies
95. NACP/α-synuclein and tau constitute two distinctive subsets of filaments in the same neuronal inclusions in brains from a family of parkinsonism and dementia with Lewy bodies: Double-immunolabeling fluorescence and electron microscopic studies
96. Occurrence of α-synuclein immunoreactive neurons with neurufibrillary tangle formation in the limbic areas of patients with Alzheimer's disease
97. Multiple system atrophy: A sporadic synucleinopathy
98. Orthostatic hypotension and nicotine insensitivity in a case of multiple system atrophy
99. Consensus statement on the diagnosis of multiple system atrophy
100. NACP/α-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy
101. Multiple system atrophy: A new alpha-synuclein disease?
102. Alpha-synuclein in neurodegenerative disorders: Murderer or accomplice?
103. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α-synuclein
104. Immunohistochemical and biochemical studies demonstrate a distinct profile of α-synuclein permutations in multiple system atrophy
105. Co-localization of NACP/alpha-synuclein and tau in neuronal and glial cytoplasmic inclusions in a patient with multiple system atrophy of long duration
106. Degeneration process of Lewy bodies in the brains of patients with dementia with Lewy bodies using α-synuclein immunohistochemistry
107. Overexpression of human α-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells
108. Enhanced vulnerability to oxidative stress by α-synuclein mutations and C-terminal truncation
109. α-Synuclein and Parkinson's disease: Selective neurodegenerative effect of α-synuclein fragment on dopaminergic neurons in vitro and in vivo
110. Cell death mechanisms in Parkinson's disease
111. Cell death mechanisms in multiple system atrophy
112. Cyclin-dependent kinase 5 and mitogen-activated protein kinase in glial cytoplasmic inclusions in multiple system atrophy
113. Alpha-synuclein associates with transcription factor Elk-1 in glial cytoplasmic inclusion of multiple system atrophy
114. Cortical and brainstem-type Lewy bodies are immunoreactive for the cyclin-dependent kinase 5
115. Cyclin-dependent kinase 5 (Cdk5) associated with Lewy bodies in diffuse Lewy body disease
116. Midkine, a new neurotrophic factor, is present in glial cytoplasmic inclusions of multiple system atrophy brains